ADC Therapeutics (ADCT) Shares Outstanding (2019 - 2026)

ADC Therapeutics (ADCT) has reported Shares Outstanding (Entity) for 8 consecutive years, with $129.7 million the latest figure, recorded in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 27.48% year-over-year to $129.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.7 million (up 27.48% YoY) and the FY2025 annual result came in at $128.3 million, up 26.28% from the prior year.
• Shares Outstanding (Entity) climbed to $129.7 million in Q1 2026 per ADCT's latest filing, from $128.3 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for ADCT reached as high as $129.7 million in Q1 2026 and fell as low as $76.8 million in Q1 2022.
• A 5-year average of $97.5 million and a median of $89.0 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) changed 0.0% — and 2026, when it climbed 27.48%.
• Year by year, Shares Outstanding (Entity) stood at $89.0 million in 2022, then changed by 0.0% to $89.0 million in 2023, then increased by 14.11% to $101.6 million in 2024, then gained by 26.28% to $128.3 million in 2025, then increased by 1.1% to $129.7 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $129.7 million, $128.3 million, and $115.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.